EP2364154A4 - Compositions et procédés pour traiter des affections véhiculées par la métalloprotéinase matricielle 9 (mmp9) - Google Patents

Compositions et procédés pour traiter des affections véhiculées par la métalloprotéinase matricielle 9 (mmp9)

Info

Publication number: EP2364154A4
Authority: EP; European Patent Office
Prior art keywords: mmp9; compositions; methods; matrix metalloproteinase; mediated conditions
Prior art date: 2008-10-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP09822743.2A

Other languages

German (de)

English (en)

Other versions

EP2364154A1 (fr

Inventor

Richard L Watson

Anthony B Wood

Gregory J Archambeau

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Microdiffusion Inc

Original Assignee

Microdiffusion Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-22

Filing date

2009-10-22

Publication date

2013-07-10

2008-10-24 Priority claimed from US12/258,210 external-priority patent/US20090274730A1/en

2009-10-22 Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc

2011-09-14 Publication of EP2364154A1 publication Critical patent/EP2364154A1/fr

2013-07-10 Publication of EP2364154A4 publication Critical patent/EP2364154A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Oncology (AREA)
Psychology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)

EP09822743.2A 2008-10-22 2009-10-22 Compositions et procédés pour traiter des affections véhiculées par la métalloprotéinase matricielle 9 (mmp9) Withdrawn EP2364154A4 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US10748008P	2008-10-22	2008-10-22
US10745308P	2008-10-22	2008-10-22
US12/258,210 US20090274730A1 (en)	2007-10-25	2008-10-24	Compositions and methods for treating inflammation
PCT/US2009/061744 WO2010048455A1 (fr)	2008-10-22	2009-10-22	Compositions et procédés pour traiter des affections véhiculées par la métalloprotéinase matricielle 9 (mmp9)

Publications (2)

Publication Number	Publication Date
EP2364154A1 EP2364154A1 (fr)	2011-09-14
EP2364154A4 true EP2364154A4 (fr)	2013-07-10

Family

ID=42119683

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP09822721.8A Withdrawn EP2350263A4 (fr)	2008-10-22	2009-10-22	Compositions et procédés pour le traitement d'affections médiées par la lymphopoïétine stromale thymique (tslp)
EP09822743.2A Withdrawn EP2364154A4 (fr)	2008-10-22	2009-10-22	Compositions et procédés pour traiter des affections véhiculées par la métalloprotéinase matricielle 9 (mmp9)

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP09822721.8A Withdrawn EP2350263A4 (fr)	2008-10-22	2009-10-22	Compositions et procédés pour le traitement d'affections médiées par la lymphopoïétine stromale thymique (tslp)

Country Status (9)

Country	Link
EP (2)	EP2350263A4 (fr)
JP (4)	JP5688371B2 (fr)
CN (2)	CN102256607B (fr)
AU (2)	AU2009308302B2 (fr)
BR (2)	BRPI0920430A2 (fr)
CA (2)	CA2741336A1 (fr)
IL (2)	IL212277A0 (fr)
MX (2)	MX337035B (fr)
WO (2)	WO2010048425A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6702949B2 (en)	1997-10-24	2004-03-09	Microdiffusion, Inc.	Diffuser/emulsifier for aquaculture applications
JP5306214B2 (ja)	2006-10-25	2013-10-02	リバルシオコーポレイション	混合装置
JP5595041B2 (ja)	2006-10-25	2014-09-24	リバルシオコーポレイション	酸素富化溶液を用いる、眼および他のヒト組織の治療処置の方法
US8445546B2 (en)	2006-10-25	2013-05-21	Revalesio Corporation	Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US9745567B2 (en)	2008-04-28	2017-08-29	Revalesio Corporation	Compositions and methods for treating multiple sclerosis
US10125359B2 (en)	2007-10-25	2018-11-13	Revalesio Corporation	Compositions and methods for treating inflammation
US9523090B2 (en)	2007-10-25	2016-12-20	Revalesio Corporation	Compositions and methods for treating inflammation
AU2009241365B2 (en) *	2008-04-28	2015-01-22	Revalesio Corporation	Compositions and methods for treating multiple sclerosis
CN102076327B (zh)	2008-05-01	2014-04-16	利发利希奥公司	治疗消化功能紊乱的组合物和方法
US8815292B2 (en)	2009-04-27	2014-08-26	Revalesio Corporation	Compositions and methods for treating insulin resistance and diabetes mellitus
SG10201503600XA (en) *	2010-05-07	2015-06-29	Revalesio Corp	Compositions and methods for enhancing physiological performance and recovery time
BR112013003110A2 (pt)	2010-08-12	2016-06-28	Revalesio Corp	composições e métodos para tratamento de taupatia
AU2012242592B2 (en) *	2011-04-13	2016-03-10	Revalesio Corporation	Compositions and methods for inhibiting and/or modulating effector T-cells involved in inflammatory neurodegenerative disease
CN102268069B (zh) *	2011-07-01	2012-11-28	中国药科大学	基质金属蛋白酶-9多肽抑制剂4及其应用
CN102250213B (zh) *	2011-07-01	2012-11-07	中国药科大学	基质金属蛋白酶-9多肽抑制剂3及其应用
CN102268070B (zh) *	2011-07-01	2012-11-28	中国药科大学	基质金属蛋白酶-9多肽抑制剂2及其应用
KR101492435B1 (ko) *	2012-12-28	2015-02-10	고려대학교 산학협력단	ＨＩＦ１α ｓｉＲＮＡ를 유효성분으로 함유하는 ＴＳＬＰ에 의해 매개되는 질환 예방 또는 치료용 약제학적 조성물
GB201300684D0 (en)	2013-01-15	2013-02-27	Apitope Int Nv	Peptide
CN105477628B (zh) *	2014-09-19	2021-04-30	山东蓝金生物工程有限公司	抗癌组合物及其用途
CN106943593A (zh) *	2017-03-24	2017-07-14	浙江中医药大学	抗tslp抗体在制备防治慢性瘙痒药物中的应用
WO2019005948A1 (fr) *	2017-06-27	2019-01-03	Translational Sciences, Inc.	Inhibition de la métalloprotéinase matricielle 9 vasculaire pour traiter une lésion ischémique
CN114126623A (zh) *	2019-05-17	2022-03-01	宾夕法尼亚大学董事会	治疗肥胖和/或皮肤紊乱的方法和组合物
CN112876564B (zh) *	2019-11-29	2022-07-15	康诺亚生物医药科技（成都）有限公司	一种tslp相关病症治疗剂的开发和应用
WO2025076280A1 (fr)	2023-10-05	2025-04-10	Ashibio, Inc.	Méthodes et compositions de traitement de troubles médiés par la mmp-9

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030232114A1 (en) *	2002-06-13	2003-12-18	Nikola Dekleva	Method for liquid enrichment with oxygen and applications of enriched liquids
WO2004022098A1 (fr) *	2002-09-09	2004-03-18	Borsos Ferenc	Eau enrichie en oxygene, traitee dans un champ magnetique et eau lourde
US20070259032A1 (en) *	2006-05-01	2007-11-08	Corinne Bright	Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
WO2008052143A2 (fr) *	2006-10-25	2008-05-02	Revalesio Corporation	Dispositif de mélange et ses fluides de sortie
WO2009055614A1 (fr) *	2007-10-25	2009-04-30	Revalesio Corporation	Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire
WO2009134728A2 (fr) *	2008-04-28	2009-11-05	Revalesio Corporation	Compositions et procédés pour traiter la sclérose en plaques

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU764180B2 (en) *	1998-07-28	2003-08-14	Regents Of The University Of California, The	Nucleic acids encoding a G-protein coupled receptor involved in sensory transduction
EP2322226A3 (fr) *	1999-07-21	2011-08-17	Omeros Corporation	Solutions et procédés pour l'inhibition de la douleur, la inflammation et la degradation du cartilage
US20040235732A1 (en) *	2000-11-03	2004-11-25	Qun-Yong Zhou	Method for modulating angiogenesis using prokineticin receptor antagonists
US20070077553A1 (en) *	2003-10-30	2007-04-05	Rosetta Genomics	Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
EP1599165A4 (fr) *	2003-02-10	2010-09-08	Univ Jefferson	Utilisation de ligands gcc
US20090010920A1 (en) *	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
US7393924B2 (en) *	2004-01-06	2008-07-01	Franco Vitaliano	Smart bio-nanoparticle elements
KR100583430B1 (ko) *	2004-03-08	2006-05-24	양경숙	차륜 가변형 스쿠터
US20050249712A1 (en) *	2004-03-23	2005-11-10	The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services	Methods for use of TSLP and agonists and antagonists thereof
US20080050452A1 (en) *	2006-06-30	2008-02-28	Nucryst Pharmaceuticals	Metal-containing formulations and methods of use
JP5595041B2 (ja) *	2006-10-25	2014-09-24	リバルシオコーポレイション	酸素富化溶液を用いる、眼および他のヒト組織の治療処置の方法
WO2008115290A2 (fr) *	2006-10-25	2008-09-25	Revalesio Corporation	Méthodes de soins et de traitement de plaies

2009
- 2009-10-22 CA CA2741336A patent/CA2741336A1/fr not_active Abandoned
- 2009-10-22 JP JP2011533355A patent/JP5688371B2/ja not_active Expired - Fee Related
- 2009-10-22 BR BRPI0920430A patent/BRPI0920430A2/pt not_active IP Right Cessation
- 2009-10-22 MX MX2011004235A patent/MX337035B/es active IP Right Grant
- 2009-10-22 EP EP09822721.8A patent/EP2350263A4/fr not_active Withdrawn
- 2009-10-22 CN CN200980151711.6A patent/CN102256607B/zh not_active Expired - Fee Related
- 2009-10-22 CA CA2741341A patent/CA2741341A1/fr active Pending
- 2009-10-22 JP JP2011533341A patent/JP5688370B2/ja not_active Expired - Fee Related
- 2009-10-22 AU AU2009308302A patent/AU2009308302B2/en not_active Ceased
- 2009-10-22 MX MX2011004233A patent/MX2011004233A/es active IP Right Grant
- 2009-10-22 AU AU2009308362A patent/AU2009308362B2/en not_active Ceased
- 2009-10-22 EP EP09822743.2A patent/EP2364154A4/fr not_active Withdrawn
- 2009-10-22 BR BRPI0920201A patent/BRPI0920201A2/pt not_active IP Right Cessation
- 2009-10-22 CN CN200980151710.1A patent/CN102257130B/zh not_active Expired - Fee Related
- 2009-10-22 WO PCT/US2009/061710 patent/WO2010048425A1/fr not_active Ceased
- 2009-10-22 WO PCT/US2009/061744 patent/WO2010048455A1/fr not_active Ceased
2011
- 2011-04-12 IL IL212277A patent/IL212277A0/en unknown
- 2011-04-13 IL IL212309A patent/IL212309A/en not_active IP Right Cessation
2014
- 2014-12-05 JP JP2014246760A patent/JP2015044869A/ja not_active Withdrawn
- 2014-12-05 JP JP2014246753A patent/JP2015044868A/ja not_active Withdrawn

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030232114A1 (en) *	2002-06-13	2003-12-18	Nikola Dekleva	Method for liquid enrichment with oxygen and applications of enriched liquids
WO2004022098A1 (fr) *	2002-09-09	2004-03-18	Borsos Ferenc	Eau enrichie en oxygene, traitee dans un champ magnetique et eau lourde
US20070259032A1 (en) *	2006-05-01	2007-11-08	Corinne Bright	Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
WO2008052143A2 (fr) *	2006-10-25	2008-05-02	Revalesio Corporation	Dispositif de mélange et ses fluides de sortie
WO2009055614A1 (fr) *	2007-10-25	2009-04-30	Revalesio Corporation	Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire
WO2009134728A2 (fr) *	2008-04-28	2009-11-05	Revalesio Corporation	Compositions et procédés pour traiter la sclérose en plaques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HANS LASSMANN: "Hypoxia-like tissue injury as a component of multiple sclerosis lesions", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 206, no. 2, 15 February 2003 (2003-02-15), pages 187 - 191, XP008137062, ISSN: 0022-510X, DOI: 10.1016/S0022-510X(02)00421-5 *
See also references of WO2010048455A1 *

Also Published As

Publication number	Publication date
AU2009308362A1 (en)	2010-04-29
CA2741336A1 (fr)	2010-04-29
JP2015044869A (ja)	2015-03-12
CN102256607B (zh)	2014-11-05
MX2011004233A (es)	2011-06-24
EP2350263A1 (fr)	2011-08-03
BRPI0920201A2 (pt)	2019-09-10
MX2011004235A (es)	2011-06-24
AU2009308362B2 (en)	2016-02-04
CN102257130A (zh)	2011-11-23
JP2015044868A (ja)	2015-03-12
CN102256607A (zh)	2011-11-23
WO2010048425A1 (fr)	2010-04-29
EP2364154A1 (fr)	2011-09-14
MX337035B (es)	2016-02-09
CA2741341A1 (fr)	2010-04-29
JP5688370B2 (ja)	2015-03-25
AU2009308302A1 (en)	2010-04-29
IL212277A0 (en)	2011-06-30
IL212309A (en)	2016-04-21
AU2009308302B2 (en)	2016-01-21
BRPI0920430A2 (pt)	2019-09-24
EP2350263A4 (fr)	2013-07-03
JP5688371B2 (ja)	2015-03-25
JP2012506453A (ja)	2012-03-15
WO2010048455A1 (fr)	2010-04-29
CN102257130B (zh)	2016-07-06
IL212309A0 (en)	2011-06-30
JP2012506451A (ja)	2012-03-15

Publication	Publication Date	Title
EP2364154A4 (fr)	2013-07-10	Compositions et procédés pour traiter des affections véhiculées par la métalloprotéinase matricielle 9 (mmp9)
HRP20190214T1 (hr)	2019-03-22	Pripravci i metode za liječenje purpure
SMT202300082T1 (it)	2023-05-12	Metodi e composizioni per il trattamento dei disturbi associati al complemento
PL2268612T3 (pl)	2015-02-27	Arylosulfonamidowe inhibitory metaloproteinaz macierzy
EP2170309A4 (fr)	2010-11-03	Procédés et compositions pour le traitement de troubles
PL3009148T3 (pl)	2019-03-29	Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
EP2120561A4 (fr)	2012-11-21	Compositions pour traiter des biofilms, et procédés pour leur utilisation
IL185540A0 (en)	2008-08-07	Compositions and methods for treating acne
IL209032A0 (en)	2011-01-31	Compositions and methods for treating digestive disorders
IL210097A0 (en)	2011-02-28	Compositions and methods for treating unfluenza
GB2466912B (en)	2012-01-04	Compositions and methods for treating lysosomal disorders
SI2520295T1 (sl)	2016-11-30	Postopki za preprečevanje in zdravljenje mukozitisa
EP2125887A4 (fr)	2010-11-10	Compositions et procedes utilises pour le diagnostic et le traitement du cancer
ZA200900140B (en)	2009-12-30	Methods and compositions for treating biofilms
EP2155249A4 (fr)	2011-11-16	Compositions et procédés pour le diagnostic et le traitement du cancer
GB0704718D0 (en)	2007-04-18	Compounds and methods for preventing and treating mucositis
HUP0700369D0 (en)	2007-07-30	Pharmaceutical compositions and method for treating schizofrenia
EP2323579A4 (fr)	2014-05-14	Procédés et dispositifs pour traiter la presbytie
EP2294199A4 (fr)	2011-06-15	Compositions et procédés pour améliorer des plantes
IL211904A0 (en)	2011-06-30	Composition for treating disese
IL196638A0 (en)	2009-11-18	Methods and compositions for treating disease
ZA201004212B (en)	2012-11-28	Method and composition for treating an alpha adrenoceptor-mediated condition
EP2424549A4 (fr)	2012-11-21	Compositions et méthodes de traitement et de prévention des lithiases urinaires et des affections associées
ZA201006657B (en)	2011-11-30	Disinfection composition and process
EP2094279A4 (fr)	2010-12-29	Procédés et compositions pour traiter la grippe

Legal Events

Date	Code	Title	Description
2011-08-12	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2011-09-14	17P	Request for examination filed	Effective date: 20110520
2011-09-14	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2012-01-25	DAX	Request for extension of the european patent (deleted)
2013-07-10	A4	Supplementary search report drawn up and despatched	Effective date: 20130607
2013-07-10	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 9/00 20060101AFI20130603BHEP Ipc: A61K 31/573 20060101ALI20130603BHEP Ipc: A61K 45/06 20060101ALI20130603BHEP Ipc: A61K 33/00 20060101ALI20130603BHEP Ipc: A61K 31/00 20060101ALI20130603BHEP
2015-09-30	17Q	First examination report despatched	Effective date: 20150828
2017-09-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2017-10-04	18D	Application deemed to be withdrawn	Effective date: 20170503